Researchers found a key indicator of ovarian cancer aggressiveness in the glutamine ratio between external and internal sources. A high ratio is associated with tumor aggression and poor survival rates.
Researchers at Georgia State University identify two enzymes that suppress proteins important for cell survival and chemoresistance in ovarian cancer. Their findings suggest inhibiting these enzymes could be a novel therapeutic approach to overcoming resistance.
Scientists have identified a potential new strategy to treat ovarian cancer by targeting multiple growth factors. By blocking several avenues that tumour cells use to escape eradication, researchers hope to develop new anticancer drugs that target ovarian tumour growth.
Researchers inhibit heat shock protein 90, shutting off proteases that help ovarian cancer cells escape and spread. In mouse studies, ganetespib treatment reduced metastases, indicating potential therapeutic target for ovarian cancer.
Researchers at Fox Chase Cancer Center have identified FAK as a potential target for epithelial ovarian cancer treatment. By inhibiting the activity of FAK, they found that STAT3 activation was reduced, suggesting that targeting this enzyme could also inhibit the action of STAT3 in epithelial ovarian cancer cells.
Researchers from Fox Chase Cancer Center found that NEDD9 protein activates oncogenic signaling pathways in cancer cells, encouraging metastases. The study suggests the protein plays an important role in initial development and dissemination of ovarian cancer.
Researchers uncover complement pathway as primary immune mechanism driving endometriosis and ovarian cancer development. The discovery may lead to targeted preventive measures, such as immune therapy, for women with endometriosis at increased cancer risk.
A new study found that ovarian cancer patients' disease-free survival rates significantly improved over time, particularly among those with poorer initial prognoses. The research suggests that considering the time elapsed since remission may provide a more accurate prognosis and inform better follow-up care decisions.
Scientists have identified a set of proteins called TAFs that may play a role in the development of ovarian cancer. Studies found that these proteins are overexpressed or underexpressed in 73% of tumors, suggesting they could be potential targets for new treatments.
A new glycoprofiling test has been developed to halve the number of false-positives in ovarian cancer diagnoses, sparing women from unnecessary worry and further testing. The test targets a specific sugar molecule on the CA125 protein, which is only present in women with ovarian cancer.
A large international study found that women with BRCA1 mutations who underwent preventive ovarian surgery before age 35 had a 77% reduction in total mortality risk. In contrast, women with BRCA2 mutations may delay this procedure until their 40s.
Researchers have developed a biologic drug that prevents the production of HE4 protein, allowing ovarian cancer cells to grow aggressively and resist chemotherapy. The novel biologic has shown promising results in cell and animal models, increasing the potential for improved treatment and survival rates for women with ovarian cancer.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
A new study estimates that one in five women with ovarian cancer has an inherited genetic mutation that increases their risk of developing the disease. The research identified 222 inherited genetic variants associated with ovarian cancer, including major changes in genes critical for DNA repair and cell division.
Researchers at Case Comprehensive Cancer Center have identified a microRNA biomarker, miR-181a, that predicts treatment response in ovarian cancer. Elevated levels of miR-181a are associated with chemotherapy resistance and disease progression.
A study by Manchester scientists found that women who undergo risk-reducing surgery have increased survival rates compared to those who don't. The research suggests that removing ovaries and fallopian tubes can reduce the risk of both ovarian and breast cancer by half.
Researchers at Cedars-Sinai have discovered a 10-gene biomarker panel that can identify the aggressiveness of ovarian cancer, predict survival outcomes, and inform novel therapeutic strategies. The study suggests that this biomarker panel may have predictive value and biological relevance for treating patients with ovarian cancer.
Researchers at Rutgers University have developed a targeted drug delivery system that successfully treats advanced-stage ovarian cancer in mice. The treatment involves using small inhibiting RNA molecules to decrease excess CD44 protein in cancer cells while treating with anti-cancer drug paclitaxel.
A microchip-based device developed by MGH researchers may simplify the monitoring of patients' response to treatment for ovarian cancer. The team isolated and identified tumor cells from ascites, an accumulation of fluid in the abdomen that often occurs in abdominal cancers.
Scientists at Fred Hutchinson Cancer Center developed a method to count tumor-infiltrating T lymphocytes reliably and quickly, which correlates with improved survival rates. The technology has the potential to predict treatment response, cancer recurrence, and disease-free survival earlier and more effectively.
A comprehensive study reveals unprecedented genetic variation in ovarian cancer, highlighting potential new pathways for therapeutic intervention. The research suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.
Researchers at Oregon State University developed a nanotech system that combines heat and chemotherapeutic drugs to kill 95% of ovarian cancer cells. The system uses iron oxide nanoparticles coated with a cancer-killing drug, which are heated using an oscillating magnetic field, improving efficacy while minimizing side effects.
A study by UCL researchers found that abnormal levels of female hormones are a possible explanation for why women with BRCA1/2 mutations develop breast and ovarian cancer. The research suggests that targeting these hormones could lead to new ways of preventing cancers in high-risk women.
A new study found that targeted treatment and conventional chemotherapy can be effective in treating ovarian cancer, particularly in women with BRCA gene mutations. The treatment combination showed promising results in patients who had previously developed resistance to PARP inhibitor drugs.
Researchers have identified fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. The study found that overexpression of the FGF18 gene is associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
Researchers at Massachusetts General Hospital identify fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. Overexpression of the gene encoding FGF18 was associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
A 12-year study found CA-125 to have a 99.9% specificity in detecting high-grade invasive ovarian cancers at curable stages, while the test failed to detect two borderline cases. The study's results suggest CA-125 as a promising first step in early disease detection.
A new screening strategy for ovarian cancer has shown high specificity in detecting the disease before it becomes lethal. The two-stage approach incorporates changes in a blood protein called CA125 and has been found to have a positive predictive value of 40% for invasive ovarian cancer.
Researchers identified protein biomarkers that predict ovarian cancer recurrence and chronic obstructive pulmonary disease (COPD) development. The findings suggest a potential for using protein analysis to predict patient outcomes and guide treatment decisions in both diseases.
A new biomarker, PROVAR, predicts time to ovarian cancer recurrence and distinguishes between high-risk patients. Analysis of protein biomarkers may help determine treatment plans for ovarian cancer patients.
Researchers at Stanford University and Akira University in Japan have discovered a new hormone called R-spondin2 that promotes follicle development and stimulates ovary growth. The hormone, produced by human female eggs, may lead to new infertility treatment options when used with traditional Follicle Stimulating Hormone (FSH).
Researchers developed a novel approach to make ovarian cancer cells susceptible to an antitumor drug, potentially improving treatment outcomes. The strategy targets telomeres and shows promise in treating other epithelial cancers.
A major international study has found that sequence differences in a gene crucial to chromosome integrity predispose individuals to certain cancers. The study, published in Nature Genetics, identified variations in the TERT gene as influencing telomere length and breast and ovarian cancer risk.
The team identified 21 microRNAs associated with ovarian cancer survival and 838 target genes linked to its progression. The findings suggest a network-based approach can predict cancer survival and recurrence more accurately than individual biomarkers.
A Northwestern University study has developed a pioneering biophotonics technology to detect ovarian cancer by analyzing cells from the cervix or uterus. The partial wave spectroscopic microscopy technique shows diagnostic changes in these cells even when they appear normal under a microscope, offering a potential breakthrough in early...
Researchers identified three BRCA1 gene variants as pathogenic, increasing breast and ovarian cancer risk. These findings will improve genetic counseling and allow for personalized cancer assessment.
A study found that ATP11B expression is correlated with higher tumor grade and cisplatin-resistance in human ovarian cancer samples. Loss of ATP11B restored sensitivity to cisplatin and reduced ovarian tumor growth in mice.
A novel study suggests that surgical removal of an ovary and visible endometriosis significantly lower ovarian cancer risk in women with endometriosis. Hormonal treatments, however, did not show a protective effect against ovarian cancer.
A new two-step immunotherapy approach, combining dendritic cell vaccination and adoptive T-cell therapy, showed a 75% clinical benefit in 31 ovarian cancer patients. The treatment preserved tumor cells alive and used them to manufacture personalized vaccines that taught the immune system to attack the tumor.
A phase I trial involving 29 patients with platinum-resistant ovarian cancer found one complete response and four partial responses to the antibody-drug conjugate DMUC5754A. The drug targets high-expression MUC16 protein in ovarian cancer cells, reducing adverse effects on healthy tissues.
Researchers at Mayo Clinic Cancer Center have identified new DNA sequences linked to an increased risk of developing breast and ovarian cancers. The findings, published in three studies, will help improve risk models and support new prevention strategies for these diseases.
Researchers at Mayo Clinic Cancer Center identified the HNF1B gene as a contributor to ovarian cancer susceptibility through large-scale analysis of over 16,000 women. Variations in this gene are associated with different ovarian cancer subtypes and DNA methylation patterns.
Researchers have discovered five new genetic regions associated with an increased risk of ovarian cancer, found in over 40,000 women. These findings may lead to the development of new screening and prevention strategies for high-risk individuals.
An international study has identified up to 80 new regions of the genome associated with increased susceptibility to breast, prostate, and ovarian cancers. Researchers have also discovered a total of 41 new genes or regions that may contribute to the development of breast cancer.
Moffitt researchers have discovered four new regions of the genome linked to ovarian cancer risk, accounting for approximately 4% of inherited component. The findings are part of a coordinated series of studies involving over 250,000 individuals and provide new insights into the disease.
Research published in Occupational and Environmental Medicine found that night shift workers have a higher risk of developing ovarian cancer. Women who identified as 'owls' had a lower risk compared to those who were 'larks'. The study, based on data from over 1,100 women, suggests that melatonin may play a role in the increased risk.
Researchers found a population of slow-proliferating epithelial cells in the mouse ovary's hilum region that can self-renew and form tumors. These cells were previously unknown and are now believed to be the source of ovarian stem-like cells prone to cancer.
A novel stem cell niche for the ovarian surface epithelium has been identified, where ovarian carcinoma preferentially originates. This discovery provides a new guide for scientists to look for stem cell niches and sources of cancer in other transitional zones.
Researchers found a potential therapeutic candidate, miR-506, which blocks epithelial-to-mesenchymal transition and inhibits mesenchymal markers in ovarian cancer cells. Higher miR-506 expression is associated with longer overall survival.
A groundbreaking study published in PLOS ONE names a new cell type playing a key role in ovary and ovarian follicle development, challenging conventional thinking. This discovery may lead to better understanding and treatment of infertility, premature ovarian failure, and ovarian cancer.
A phase II clinical trial shows that selumetinib, a targeted therapy, can halt growth or shrink tumors in 15% of patients with recurrent low-grade ovarian cancer. The two-year overall survival rate is 55%, and the median overall survival has not been reached due to high patient survival rates.
A two-step personalized immunotherapy treatment using dendritic cell vaccine and adoptive T cell therapy has triggered anti-tumor immune responses in patients with late-stage ovarian cancer. Four of six patients treated responded to the therapy, showing promising early results.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
Researchers created a genomic sequencing test, 'PapGene', using cervical fluid from routine Pap tests to detect ovarian and endometrial cancers with high accuracy. The test distinguished cancerous DNA from normal DNA, detecting both early and late-stage diseases.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
Among eligible women, 19.1% underwent risk-reducing salpingo-oophorectomy (RRSO) and 39.6% used screening procedures, with women receiving a positive BRCA test result having increased odds of these interventions, while true-negative results were associated with reduced odds.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.